Lupin Partners With Biomm To Launch Pegfilgrastim Biosimilar In Brazil

Filing For The Neulasta Biosimilar Was Accepted By The US FDA In June

 
• By Chloe Kent

Indian pharma firm Lupin has partnered with Biomm to market its proposed Neulasta biosimilar in Brazil, as it comes to the end of a tumultuous 2021.

India and Brazil flags
Biomm will distribute Lupin's pegfilgrastim generic in Brazil • Source: Alamy

More from Biosimilars

More from Products